Accelerated discovery a triple threat to triple negative breast cancer

Houston Methodist Hospital researchers have advanced a potential treatment for metaplastic breast cancer–the most aggressive subtype of triple negative breast cancer, into patients in just under four years. In a study published in the Journal of the National Cancer Institute (early online Dec. 31), a multi-institutional team led by Jenny C. Chang, M.D., director of the Houston Methodist Cancer Center, identified a gene driving the formation of metaplastic breast cancer. “We not only uncovered the biological pathway stimulating cancer growth, but we found a compound that blocked it, increasing the survival of mice carrying human metaplastic breast tumors,” said Chang,…
View More/Source Article